Michael N. Neely

Michael N. Neely

Professor of Pediatrics (Clinical Scholar);CHLA Division Chief of Infectious Diseases
CHLA 4650 W. Sunset Blvd. Off Campus Los Angeles

Developing new drugs for the therapy of Mycobacterium tuberculosis: What information do we get from pre-clinical animal models? Antimicrob Agents Chemother. 2020 Sep 21.. View in PubMed

Building optimal 3-drug combination chemotherapy regimens Antimicrob Agents Chemother. 2020 Sep 08. . View in PubMed

Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model Antimicrob Agents Chemother. 2020 Aug 20; 64(9). . View in PubMed

Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients Antimicrob Agents Chemother. 2020 Aug 20; 64(9). . View in PubMed

Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing Antimicrob Agents Chemother. 2020 Aug 20; 64(9). . View in PubMed

How to design a study to evaluate therapeutic drug monitoring in infectious diseases? Clin Microbiol Infect. 2020 Aug; 26(8):1008-1016.. View in PubMed

Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children Clin Pharmacokinet. 2020 Aug; 59(8):1049-1061. . View in PubMed

Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime Clin Pharmacokinet. 2020 Aug; 59(8):1027-1036. . View in PubMed

Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate Clin Pharmacokinet. 2020 Jul; 59(7):885-898. . View in PubMed

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper Intensive Care Med. 2020 Jun; 46(6):1127-1153. . View in PubMed

Development and Implementation of Electronic Health Record-Integrated Model-Informed Clinical Decision Support Tools for the Precision Dosing of Drugs Clin Pharmacol Ther. 2020 01; 107(1):129-135. . View in PubMed

Development of a methodology to make individual estimates of the precision of liquid chromatography-tandem mass spectrometry drug assay results for use in population pharmacokinetic modeling and the optimization of dosage regimens PLoS One. 2020; 15(3):e0229873. . View in PubMed

Development of Chronic Pseudomonas aeruginosa-Positive Respiratory Cultures in Children with Tracheostomy Lung. 2019 12; 197(6):811-817. . View in PubMed

Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis Ther Drug Monit. 2019 12; 41(6):719-725. . View in PubMed

Optimizing Gentamicin Dosing in Pediatrics Using Monte Carlo Simulations Pediatr Infect Dis J. 2019 04; 38(4):390-395. . View in PubMed

Early Use of Anti-influenza Medications in Hospitalized Children With Tracheostomy Pediatrics. 2019 03; 143(3). . View in PubMed

Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children Bone Marrow Transplant. 2019 03; 54(3):448-457. . View in PubMed

In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae J Antimicrob Chemother. 2019 12 01; 74(12):3521-3529. . View in PubMed

Length of Stay and Hospital Revisit After Bacterial Tracheostomy-Associated Respiratory Tract Infection Hospitalizations Hosp Pediatr. 2018 Jan 16. . View in PubMed

Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model Antimicrob Agents Chemother. 2018 12; 62(12). . View in PubMed

Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs Clin Pharmacol Ther. 2018 11; 104(5):966-973. . View in PubMed

Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology J Clin Pharmacol. 2018 10; 58 Suppl 10:S73-S85. . View in PubMed

Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model Antimicrob Agents Chemother. 2018 08; 62(8). . View in PubMed

Pharmacokinetic/Pharmacodynamic Determinants of Vancomycin Efficacy in Enterococcal Bacteremia Antimicrob Agents Chemother. 2018 03; 62(3). . View in PubMed

Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing Antimicrob Agents Chemother. 2018 02; 62(2). . View in PubMed

Pharmacodynamics of teicoplanin against MRSA J Antimicrob Chemother. 2017 Dec 01; 72(12):3382-3389. . View in PubMed

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response Clin Infect Dis. 2017 Jun 01; 64(11):1557-1563. . View in PubMed

Is continuous infusion of imipenem always the best choice? Int J Antimicrob Agents. 2017 Mar; 49(3):348-354.. View in PubMed

Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin Mol Cancer Res. 2017 12; 15(12):1704-1713. . View in PubMed

A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics Clin Pharmacokinet. 2017 04; 56(4):435-447. . View in PubMed

Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole¹ J Pharmacokinet Pharmacodyn. 2017 04; 44(2):95-111. . View in PubMed

Correction for Rhodes et al, Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. Antimicrob Agents Chemother. 2017 04; 61(4). . View in PubMed

Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones Expert Opin Drug Metab Toxicol. 2016 May; 12(5):533-44. . View in PubMed

Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy Antimicrob Agents Chemother. 2016 Apr; 60(4):2336-42. . View in PubMed

An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity J Infect Chemother. 2016 Feb; 22(2):78-83. . View in PubMed

Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity? J Antimicrob Chemother. 2016 Feb; 71(2):484-9.. View in PubMed

Closing the Brief Case: Neonatal Meningitis Caused by Listeria monocytogenes Diagnosed by Multiplex Molecular Panel J Clin Microbiol. 2016 12; 54(12):3075. . View in PubMed

Dosage Adjustments Related to Young or Old Age and Organ Impairment J Clin Pharmacol. 2016 12; 56(12):1461-1473. . View in PubMed

Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy J Antimicrob Chemother. 2016 11; 71(11):3168-3178. . View in PubMed

A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients Ther Drug Monit. 2016 10; 38(5):593-9. . View in PubMed

Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats Antimicrob Agents Chemother. 2016 10; 60(10):5742-51. . View in PubMed

Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software Ther Drug Monit. 2016 06; 38(3):332-42. . View in PubMed

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1401-10. . View in PubMed

Characterisation of a multidrug-resistant meningitic Escherichia coli strain (O75:K1:H5) isolated from an infant that is sensitive to memantine, a newly identified host-directed antimicrobial drug Int J Antimicrob Agents. 2015 Nov; 46(5):598-600. . View in PubMed

Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study Transplantation. 2015 Oct; 99(10):2158-66. . View in PubMed

Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs Antimicrob Agents Chemother. 2015 Sep; 59(9):5181-9. . View in PubMed

Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis J Antimicrob Chemother. 2015 Jul; 70(7):2068-73. . View in PubMed

Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance Ther Drug Monit. 2015 Jun; 37(3):389-94. . View in PubMed

Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia J Infect Dis. 2015 Apr 15; 211(8):1326-33. . View in PubMed

Achieving target voriconazole concentrations more accurately in children and adolescents Antimicrob Agents Chemother. 2015; 59(6):3090-7. . View in PubMed

Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients Antimicrob Agents Chemother. 2015; 59(6):2986-94. . View in PubMed

Innovative approaches to optimizing the delivery of vancomycin in individual patients Adv Drug Deliv Rev. 2014 Nov 20; 77:50-7. . View in PubMed

A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults Antimicrob Agents Chemother. 2014 Nov; 58(11):6735-41. . View in PubMed

Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients Br J Clin Pharmacol. 2014 Oct; 78(4):836-46. . View in PubMed

Population pharmacokinetics of a single intramuscular administration of tulathromycin in adult desert tortoises (Gopherus agassizii) J Vet Pharmacol Ther. 2014 Oct; 37(5):500-7. . View in PubMed

Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans Neuroreport. 2014 Sep 10; 25(13):1018-23. . View in PubMed

Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy Antimicrob Agents Chemother. 2014 Jul; 58(7):4094-102. . View in PubMed

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions Lancet Infect Dis. 2014 Jun; 14(6):498-509. . View in PubMed

New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients Pediatr Transplant. 2014 Feb; 18(1):103-11. . View in PubMed

Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis PLoS One. 2014; 9(7):e101311. . View in PubMed

Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women . 2014 Jan 01; 65(1):72-7. . View in PubMed

Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014; 58(1):309-16.. View in PubMed

Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis Antimicrob Agents Chemother. 2013 Dec; 57(12):5854-9. . View in PubMed

Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa Antimicrob Agents Chemother. 2013 Dec; 57(12):5811-9. . View in PubMed

Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation Transpl Int. 2013 Dec; 26(12):1198-207. . View in PubMed

NPEST: a nonparametric method and a database for transcription start site prediction Quant Biol. 2013 Dec; 1(4):261-271. . View in PubMed

Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients J Infect Dis. 2013 Jul 15; 208(2):351-61. . View in PubMed

Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Feb; 115(2):224-32. . View in PubMed

From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine CPT Pharmacometrics Syst Pharmacol. 2012 Oct 03; 1:e9. . View in PubMed

Antiviral therapy of two patients with chromosomally-integrated human herpesvirus-6A presenting with cognitive dysfunction J Clin Virol. 2012 Sep; 55(1):40-5. . View in PubMed

Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R Ther Drug Monit. 2012 Aug; 34(4):467-76. . View in PubMed

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals Antimicrob Agents Chemother. 2012 Jun; 56(6):2959-66. . View in PubMed

High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count Ther Drug Monit. 2012 Jun; 34(3):237-41. . View in PubMed

More codeine fatalities after tonsillectomy in North American children Pediatrics. 2012 May; 129(5):e1343-7. . View in PubMed

Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients Antimicrob Agents Chemother. 2012 Apr; 56(4):1862-9. . View in PubMed

Obesity and its impact on drug therapy: are we ready for this change? Clin Pharmacokinet. 2011 Dec 01; 50(12):825-6.. View in PubMed

Posaconazole for chronic refractory coccidioidal meningitis Clin Infect Dis. 2011 Dec; 53(12):1252-4. . View in PubMed

Nonparametric population modeling and Bayesian analysis Pharmacol Res. 2011 Oct; 64(4):426. . View in PubMed

Comment: assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients Ann Pharmacother. 2011 Sep; 45(9):1171-2. . View in PubMed

CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children Ther Drug Monit. 2011 Aug; 33(4):417-24. . View in PubMed

Increased clearance of morphine in sickle cell disease: implications for pain management J Pain. 2011 May; 12(5):531-8. . View in PubMed

Incidence and predictors of invasive candidiasis associated with candidaemia in children Mycoses. 2011 Mar; 54(2):146-53. . View in PubMed

Pharmacokinetic optimization of antiretroviral therapy in children and adolescents Clin Pharmacokinet. 2011 Mar; 50(3):143-89. . View in PubMed

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers Antimicrob Agents Chemother. 2010 Nov; 54(11):4619-25. . View in PubMed

Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead AIDS Res Hum Retroviruses. 2010 Sep; 26(9):947-53. . View in PubMed

Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician J Clin Pharmacol. 2010 Jul; 50(7):842-7. . View in PubMed

Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit. 2010 Jun; 32(3):273-81.. View in PubMed

Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children J Antimicrob Chemother. 2010 Apr; 65(4):808-9; author reply 809-10. . View in PubMed

Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children Antimicrob Agents Chemother. 2009 Jun; 53(6):2532-8. . View in PubMed

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir Ther Clin Risk Manag. 2009 Jun; 5(3):595-615. . View in PubMed

Pharmacokinetics and safety of caspofungin in older infants and toddlers Antimicrob Agents Chemother. 2009 Apr; 53(4):1450-6. . View in PubMed

Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization J Clin Pharmacol. 2008 Sep; 48(9):1081-91. . View in PubMed

Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy . 2007 Jan 01; 44(1):38-42. . View in PubMed

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents Antimicrob Agents Chemother. 2005 Nov; 49(11):4536-45. . View in PubMed

Management of antiretroviral therapy in neonates, children, and adolescents Curr HIV/AIDS Rep. 2004 Jun; 1(2):97-104. . View in PubMed

Management of Antiretroviral Therapy in Neonates, Children, and Adolescents Curr Infect Dis Rep. 2003 Dec; 5(6):521-530. . View in PubMed

Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission Afr Health Sci. 2003 Aug; 3(2):61-7. . View in PubMed

Pharmacokinetic characteristics of caspofungin in two pediatric liver transplant patients Curr Ther Res Clin Exp. 2003 Feb; 64(2):127-36. . View in PubMed

Infection control in pediatric hospitals Curr Opin Infect Dis. 2001 Aug; 14(4):449-53. . View in PubMed

Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time Pediatrics. 2001 Feb; 107(2):404-5. . View in PubMed

Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients. Although Dr. Neely primarily works in the therapeutic area of infectious diseases on antiviral, antiretroviral and antifungal compounds, he has experience with other therapeutic areas. He is currently board certified in Pediatrics and Pediatric Infectious Diseases, and he is the co-Director of the Laboratory of Applied Pharmacokinetics in the University of Southern California (USC) Keck School of Medicine, working with multidisciplinary faculty collaborators in the Departments of Pediatrics, Medicine, and Preventive Medicine, in the Schools of Pharmacy and Mathematics, and the Jet Propulsion Laboratory in Pasadena, CA. With expertise in computerized drug-response modeling, he is applying his research interests to the care of his patients by operating the first HIV therapeutic drug management service at LAC+USC, which is available to all HIV providers. He also provides out- and inpatient pharmacologic consultation for a wide range of therapeutically challenging cases. In the fall of 2010, he will complete a Master’s of Science program in Clinical and Biomedical Investigations at USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling, and he has recently been appointed to the United States Food and Drug Administration Anti-infective Drug Advisory Committee. He has received NIH funding for most of his post-doctoral career, is the author of numerous papers and abstracts, and he is invited to give talks and workshops on dose individualization and optimization worldwide.
Powered by SC CTSI

Affiliated Faculty at UPC